Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the highest dose of the combination of taxotere,
cisplatin and CPT-11, that can be given without causing severe side effects. We also want to
test the safety of this drug combination and see what effects (good and bad) it has on
patients with advanced cancer for which there is no known curable treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Massachusetts General Hospital